Lab Anim Res.  2013 Sep;29(3):131-137. 10.5625/lar.2013.29.3.131.

Development and application of neural stem cells for treating various human neurological diseases in animal models

• Yi BR
• Kim SU
• Choi KC

• KMID: 2312105
• DOI: http://doi.org/10.5625/lar.2013.29.3.131

Abstract

Stem cells derived from adult tissues or the inner cell mass (ICM) of embryos in the mammalian blastocyst (BL) stage are capable of self-renewal and have remarkable potential for undergoing lineage-specific differentiation under in vitro culturing conditions. In particular, neural stem cells (NSCs) that self-renew and differentiate into major cell types of the brain exist in the developing and adult central nervous system (CNS). The exact function and distribution of NSCs has been assessed, and they represent an interesting population that includes astrocytes, oligodendrocytes, and neurons. Many researchers have demonstrated functional recovery in animal models of various neurological diseases such as stroke, Parkinson's disease (PD), brain tumors, and metastatic tumors. The safety and efficacy of stem cell-based therapies (SCTs) are also being evaluated in humans. The therapeutic efficacy of NSCs has been shown in the brain disorder-induced animal models, and animal models may be well established to perform the test before clinical stage. Taken together, data from the literature have indicated that therapeutic NSCs may be useful for selectively treating diverse types of human brain diseases without incurring adverse effects.

Keyword

Neural stem cells; Parkinson's disease; stroke; brain tumor; metastatic tumor

MeSH Terms

Adult
Animals
Astrocytes
Blastocyst
Brain
Brain Diseases
Brain Neoplasms
Central Nervous System
Embryonic Structures
Humans
Models, Animal
Neural Stem Cells
Neurons
Oligodendroglia
Parkinson Disease
Stem Cells
Stroke

Figure

• 

  Figure 1 Application of neural stem cells (NSCs) therapies. NSCs the self-renew and differentiate into major cell types of the brain exist, such as astrocytes, oligodendrocytes, and neurons, in the developing and adult central nervous system (CNS). There have been describing the effects of NSC transplantation for achieving functional recovery from CNS damage. Therefore, NSCs may be a suitable component for treating neurological diseases such as stroke, Parkinson's diseases (PD), brain tumors, primary and metastatic tumors. GFAP; glial fibrillary acidic protein, RC2: radial glial cell marker, 6-OHDA; 6-hydroxydopamine, MPTP; 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine.

Reference

1. Pauklin S, Pedersen RA, Vallier L. Mouse pluripotent stem cells at a glance. J Cell Sci. 2011; 124(Pt 22):3727–3732. PMID: 22124139.

2. Ogawa K, Saito A, Matsui H, Suzuki H, Ohtsuka S, Shimosato D, Morishita Y, Watabe T, Niwa H, Miyazono K. Activin-Nodal signaling is involved in propagation of mouse embryonic stem cells. J Cell Sci. 2007; 120(Pt 1):55–65. PMID: 17182901.

3. Dado D, Sagi M, Levenberg S, Zemel A. Mechanical control of stem cell differentiation. Regen Med. 2012; 7(1):101–116. PMID: 22168501.

4. Maul TM, Chew DW, Nieponice A, Vorp DA. Mechanical stimuli differentially control stem cell behavior: morphology, proliferation, and differentiation. Biomech Model Mechanobiol. 2011; 10(6):939–953. PMID: 21253809.

5. Ying QL, Stavridis M, Griffiths D, Li M, Smith A. Conversion of embryonic stem cells into neuroectodermal precursors in adherent monoculture. Nat Biotechnol. 2003; 21(2):183–186. PMID: 12524553.

6. Soncin F, Mohamet L, Eckardt D, Ritson S, Eastham AM, Bobola N, Russell A, Davies S, Kemler R, Merry CL, Ward CM. Abrogation of E-cadherin-mediated cell-cell contact in mouse embryonic stem cells results in reversible LIF-independent selfrenewal. Stem Cells. 2009; 27(9):2069–2080. PMID: 19544408.

7. Harting MT, Jimenez F, Xue H, Fischer UM, Baumgartner J, Dash PK, Cox CS. Intravenous mesenchymal stem cell therapy for traumatic brain injury. J Neurosurg. 2009; 110(6):1189–1197. PMID: 19301973.

8. Evans MJ, Kaufman MH. Establishment in culture of pluripotential cells from mouse embryos. Nature. 1981; 292(5819):154–156. PMID: 7242681.

9. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, Jones JM. Embryonic stem cell lines derived from human blastocysts. Science. 1998; 282(5391):1145–1147. PMID: 9804556.

10. Reubinoff BE, Pera MF, Fong CY, Trounson A, Bongso A. Embryonic stem cell lines from human blastocysts: somatic differentiation in vitro. Nat Biotechnol. 2000; 18(4):399–404. PMID: 10748519.

11. Smith AG. Embryo-derived stem cells: of mice and men. Annu Rev Cell Dev Biol. 2001; 17:435–462. PMID: 11687496.

12. Ying QL, Nichols J, Chambers I, Smith A. BMP induction of Id proteins suppresses differentiation and sustains embryonic stem cell self-renewal in collaboration with STAT3. Cell. 2003; 115(3):281–292. PMID: 14636556.

13. Vallier L, Alexander M, Pedersen RA. Activin/Nodal and FGF pathways cooperate to maintain pluripotency of human embryonic stem cells. J Cell Sci. 2005; 118(Pt 19):4495–4509. PMID: 16179608.

14. Anneren C, Cowan CA, Melton DA. The Src family of tyrosine kinases is important for embryonic stem cell self-renewal. J Biol Chem. 2004; 279(Number):31590–31598. PMID: 15148312.

15. Paling NR, Wheadon H, Bone HK, Welham MJ. Regulation of embryonic stem cell self-renewal by phosphoinositide 3-kinase-dependent signaling. J Biol Chem. 2004; 279(46):48063–48070. PMID: 15328362.

16. Kørbling M, Estrov Z. Adult stem cells for tissue repair - a new therapeutic concept? N Engl J Med. 2003; 349(6):570–582. PMID: 12904523.

17. Verfaillie CM. Adult stem cells: assessing the case for pluripotency. Trends Cell Biol. 2002; 12(11):502–508. PMID: 12446111.

18. Lee C, Hu J, Ralls S, Kitamura T, Loh YP, Yang Y, Mukouyama YS, Ahn S. The molecular profiles of neural stem cell niche in the adult subventricular zone. PLoS One. 2012; 7(11):e50501. PMID: 23209762.

19. Galli R, Gritti A, Bonfanti L, Vescovi AL. Neural stem cells: an overview. Circ Res. 2003; 92(6):598–608. PMID: 12676811.

20. Ming GL, Song H. Adult neurogenesis in the mammalian central nervous system. Annu Rev Neurosci. 2005; 28:223–250. PMID: 16022595.

21. Alvarez-Buylla A, Lim DA. For the long run: maintaining germinal niches in the adult brain. Neuron. 2004; 41(5):683–686. PMID: 15003168.

22. Martino G, Pluchino S. The therapeutic potential of neural stem cells. Nat Rev Neurosci. 2006; 7(5):395–406. PMID: 16760919.

23. Mu Y, Lee SW, Gage FH. Signaling in adult neurogenesis. Curr Opin Neurobiol. 2010; 20(4):416–423. PMID: 20471243.

24. Pluchino S, Zanotti L, Deleidi M, Martino G. Neural stem cells and their use as therapeutic tool in neurological disorders. Brain Res Brain Res Rev. 2005; 48(2):211–219. PMID: 15850660.

25. Davenport R, Dennis M. Neurological emergencies: acute stroke. J Neurol Neurosurg Psychiatry. 2000; 68(3):277–288. PMID: 10675208.

26. Lindvall O, Kokaia Z. Stem cells in human neurodegenerative disorders--time for clinical translation? J Clin Invest. 2010; 120(1):29–40. PMID: 20051634.

27. Riolobos AS, Heredia M, de la Fuente JA, Criado JM, Yajeya J, Campos J, Santacana M. Functional recovery of skilled forelimb use in rats obliged to use the impaired limb after grafting of the frontal cortex lesion with homotopic fetal cortex. Neurobiol Learn Mem. 2001; 75(3):274–292. PMID: 11300734.

28. Ding DC, Shyu WC, Chiang MF, Lin SZ, Chang YC, Wang HJ, Su CY, Li H. Enhancement of neuroplasticity through upregulation of beta1-integrin in human umbilical cord-derived stromal cell implanted stroke model. Neurobiol Dis. 2007; 27(3):339–353. PMID: 17651977.

29. Jeong SW, Chu K, Jung KH, Kim SU, Kim M, Roh JK. Human neural stem cell transplantation promotes functional recovery in rats with experimental intracerebral hemorrhage. Stroke. 2003; 34(9):2258–2263. PMID: 12881607.

30. Kelly S, Bliss TM, Shah AK, Sun GH, Ma M, Foo WC, Masel J, Yenari MA, Weissman IL, Uchida N, Palmer T, Steinberg GK. Transplanted human fetal neural stem cells survive, migrate, and differentiate in ischemic rat cerebral cortex. Proc Natl Acad Sci U S A. 2004; 101(32):11839–11844. PMID: 15280535.

31. Tanaka N, Sasahara M, Ohno M, Higashiyama S, Hayase Y, Shimada M. Heparin-binding epidermal growth factor-like growth factor mRNA expression in neonatal rat brain with hypoxic/ischemic injury. Brain Res. 1999; 827(1-2):130–138. PMID: 10320701.

32. Zhang R, Zhang Z, Wang L, Wang Y, Gousev A, Zhang L, Ho KL, Morshead C, Chopp M. Activated neural stem cells contribute to stroke-induced neurogenesis and neuroblast migration toward the infarct boundary in adult rats. J Cereb Blood Flow Metab. 2004; 24(4):441–448. PMID: 15087713.

33. Ohab JJ, Fleming S, Blesch A, Carmichael ST. A neurovascular niche for neurogenesis after stroke. J Neurosci. 2006; 26(50):13007–13016. PMID: 17167090.

34. Ding DC, Lin CH, Shyu WC, Lin SZ. Neural Stem Cells and Stroke. Cell Transplant. 2013; 22(4):619–630. PMID: 23127719.

35. Franke TF, Hornik CP, Segev L, Shostak GA, Sugimoto C. PI3K/Akt and apoptosis: size matters. Oncogene. 2003; 22(56):8983–8998. PMID: 14663477.

36. Chong ZZ, Kang JQ, Maiese K. Erythropoietin fosters both intrinsic and extrinsic neuronal protection through modulation of microglia, Akt1, Bad, and caspase-mediated pathways. Br J Pharmacol. 2003; 138(6):1107–1118. PMID: 12684267.

37. Lee HJ, Kim MK, Kim HJ, Kim SU. Human neural stem cells genetically modified to overexpress Akt1 provide neuroprotection and functional improvement in mouse stroke model. PLoS One. 2009; 4(5):e5586. PMID: 19440551.

38. Storch A, Schwarz J. Neural stem cells and Parkinson's disease. J Neurol. 2002; 249(Suppl 3):III/30–III/32.

39. Przedborski S. Pathogenesis of nigral cell death in Parkinson's disease. Parkinsonism Relat Disord. 2005; 11(Suppl 1):S3–S7. PMID: 15885625.

40. Martin HL, Teismann P. Glutathione--a review on its role and significance in Parkinson's disease. FASEB J. 2009; 23(10):3263–3272. PMID: 19542204.

41. Dickinson DA, Forman HJ. Cellular glutathione and thiols metabolism. Biochem Pharmacol. 2002; 64(5-6):1019–1026. PMID: 12213601.

42. Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron. 2003; 39(6):889–909. PMID: 12971891.

43. Yasuhara T, Matsukawa N, Hara K, Yu G, Xu L, Maki M, Kim SU, Borlongan CV. Transplantation of human neural stem cells exerts neuroprotection in a rat model of Parkinson's disease. J Neurosci. 2006; 26(48):12497–12511. PMID: 17135412.

44. Kim SU, Park IH, Kim TH, Kim KS, Choi HB, Hong SH, Bang JH, Lee MA, Joo IS, Lee CS, Kim YS. Brain transplantation of human neural stem cells transduced with tyrosine hydroxylase and GTP cyclohydrolase 1 provides functional improvement in animal models of Parkinson disease. Neuropathology. 2006; 26(2):129–140. PMID: 16708545.

45. Ovadia A, Zhang Z, Gash DM. Increased susceptibility to MPTP toxicity in middle-aged rhesus monkeys. Neurobiol Aging. 1995; 16(6):931–937. PMID: 8622784.

46. Redmond DE Jr, Bjugstad KB, Teng YD, Ourednik V, Ourednik J, Wakeman DR, Parsons XH, Gonzalez R, Blanchard BC, Kim SU, Gu Z, Lipton SA, Markakis EA, Roth RH, Elsworth JD, Sladek JR Jr, Sidman RL, Snyder EY. Behavioral improvement in a primate Parkinson's model is associated with multiple homeostatic effects of human neural stem cells. Proc Natl Acad Sci U S A. 2007; 104(29):12175–12180. PMID: 17586681.

47. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003; 63(18):5821–5828. PMID: 14522905.

48. Kim SU. Neural stem cell-based gene therapy for brain tumors. Stem Cell Rev. 2011; 7(1):130–140. PMID: 20521177.

49. Aboody KS, Brown A, Rainov NG, Bower KA, Liu S, Yang W, Small JE, Herrlinger U, Ourednik V, Black PM, Breakefield XO, Snyder EY. Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc Natl Acad Sci U S A. 2000; 97(23):12846–12851. PMID: 11070094.

50. Barresi V, Belluardo N, Sipione S, Mudò G, Cattaneo E, Condorelli DF. Transplantation of prodrug-converting neural progenitor cells for brain tumor therapy. Cancer Gene Ther. 2003; 10(5):396–402. PMID: 12719709.

51. Ehtesham M, Kabos P, Gutierrez MA, Chung NH, Griffith TS, Black KL, Yu JS. Induction of glioblastoma apoptosis using neural stem cell-mediated delivery of tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res. 2002; 62(24):7170–7174. PMID: 12499252.

52. Kim SK, Kim SU, Park IH, Bang JH, Aboody KS, Wang KC, Cho BK, Kim M, Menon LG, Black PM, Carroll RS. Human neural stem cells target experimental intracranial medulloblastoma and deliver a therapeutic gene leading to tumor regression. Clin Cancer Res. 2006; 12(18):5550–5556. PMID: 17000692.

53. Kang NH, Yi BR, Lim SY, Hwang KA, Baek YS, Kang KS, Choi KC. Human amniotic membrane-derived epithelial stem cells display anticancer activity in BALB/c female nude mice bearing disseminated breast cancer xenografts. Int J Oncol. 2012; 40(6):2022–2028. PMID: 22344679.

54. Kim KY, Yi BR, Lee HR, Kang NH, Jeung EB, Kim SU, Choi KC. Stem cells with fused gene expression of cytosine deaminase and interferon-β migrate to human gastric cancer cells and result in synergistic growth inhibition for potential therapeutic use. Int J Oncol. 2012; 40(4):1097–1104. PMID: 22159640.

55. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55(2):74–108. PMID: 15761078.

56. Yi BR, Hwang KA, Kang NH, Kim SU, Jeung EB, Kim HC, Choi KC. Synergistic effects of genetically engineered stem cells expressing cytosine deaminase and interferon-β via their tumor tropism to selectively target human hepatocarcinoma cells. Cancer Gene Ther. 2012; 19(9):644–651. PMID: 22790964.

57. Kang NH, Hwang KA, Yi BR, Lee HJ, Jeung EB, Kim SU, Choi KC. Human amniotic fluid-derived stem cells expressing cytosine deaminase and thymidine kinase inhibits the growth of breast cancer cells in cellular and xenograft mouse models. Cancer Gene Ther. 2012; 19(6):412–419. PMID: 22498724.

58. Yi BR, Kang NH, Hwang KA, Kim SU, Jeung EB, Choi KC. Antitumor therapeutic effects of cytosine deaminase and interferon-β against endometrial cancer cells using genetically engineered stem cells in vitro. Anticancer Res. 2011; 31(9):2853–2861. PMID: 21868529.

59. Yi BR, Park MA, Lee HR, Kang NH, Choi KJ, Kim SU, Choi KC. Suppression of the growth of human colorectal cancer cells by therapeutic stem cells expressing cytosine deaminase and interferon-β via their tumor-tropic effect in cellular and xenograft mouse models. Mol Oncol. 2013; 7(3):543–554. PMID: 23403306.

60. Yi BR, Choi KJ, Kim SU, Choi KC. Therapeutic potential of stem cells expressing suicide genes that selectively target human breast cancer cells: evidence that they exert tumoricidal effects via tumor tropism (review). Int J Oncol. 2012; 41(3):798–804. PMID: 22736197.

61. Biswas G, Bhagwat R, Khurana R, Menon H, Prasad N, Parikh PM. Brain metastasis--evidence based management. J Cancer Res Ther. 2006; 2(1):5–13. PMID: 17998665.

62. Ma S, Xu Y, Deng Q, Yu X. Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and Gefitinib in a Chinese population. Lung Cancer. 2009; 65(2):198–203. PMID: 19091441.

63. Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol. 2004; 22(14):2865–2872. PMID: 15254054.

64. Joo KM, Park IH, Shin JY, Jin J, Kang BG, Kim MH, Lee SJ, Jo MY, Kim SU, Nam DH. Human neural stem cells can target and deliver therapeutic genes to breast cancer brain metastases. Mol Ther. 2009; 17(3):570–575. PMID: 19127251.

65. Zhao D, Najbauer J, Annala AJ, Garcia E, Metz MZ, Gutova M, Polewski MD, Gilchrist M, Glackin CA, Kim SU, Aboody KS. Human neural stem cell tropism to metastatic breast cancer. Stem Cells. 2012; 30(2):314–325. PMID: 22084033.

66. Yi BR, Hwang KA, Kim YB, Kim SU, Choi KC. Effects of Genetically Engineered Stem Cells Expressing Cytosine Deaminase and Interferon-Beta or Carboxyl Esterase on the Growth of LNCaP Prostate Cancer Cells. Int J Mol Sci. 2012; 13(10):12519–12532. PMID: 23202910.

67. Yi BR, Kim SU, Kim YB, Lee HJ, Cho MH, Choi KC. Antitumor effects of genetically engineered stem cells expressing yeast cytosine deaminase in lung cancer brain metastases via their tumor-tropic properties. Oncol Rep. 2012; 27(6):1823–1828. PMID: 22426744.

68. Tang Y, Shah K, Messerli SM, Snyder E, Breakefield X, Weissleder R. In vivo tracking of neural progenitor cell migration to glioblastomas. Hum Gene Ther. 2003; 14(13):1247–1254. PMID: 12952596.

69. Vermes A, Guchelaar HJ, Dankert J. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother. 2000; 46(2):171–179. PMID: 10933638.

70. Okano H. Stem cell biology of the central nervous system. J Neurosci Res. 2002; 69(6):698–707. PMID: 12205662.

71. Gage FH. Mammalian neural stem cells. Science. 2000; 287(5457):1433–1438. PMID: 10688783.